Wedbush restated their outperform rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) in a report issued on Wednesday morning, Benzinga reports. The firm currently has a $11.00 price objective on the stock. Wedbush also issued estimates for Monte Rosa Therapeutics’ Q2 2024 earnings at ($0.37) EPS, Q3 2024 earnings at ($0.34) EPS, […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Research analysts at Wedbush upped their Q2 2024 earnings per share estimates for Monte Rosa Therapeutics in a note issued to investors on Tuesday, May 21st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.37) per share for the quarter, up […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Investment analysts at Wedbush issued their FY2023 earnings estimates for Monte Rosa Therapeutics in a report released on Wednesday, February 14th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($2.63) per share for the year. Wedbush currently has a “Outperform” rating and […]
Monte Rosa Therapeutics (NASDAQ:GLUE) Now Covered by Analysts at Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Analysts at Wedbush began coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price target points to a potential upside of 131.09% from the company’s current price. Separately, […]